臺灣健保癌症用藥事前審查實作指引
1.0.1 - release
臺灣健保癌症用藥事前審查實作指引
1.0.1 - release
This page is part of the 臺灣癌症用藥事前審查實作指引(TWPAS IG) (v1.0.1: Release) based on FHIR (HL7® FHIR® Standard) R4. This is the current published version. For a full list of available versions, see the Directory of published versions
| Active as of 2024-12-06 |
{
"resourceType" : "CodeSystem",
"id" : "nhi-apply-reason",
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p class=\"res-header-id\"><b>Generated Narrative: CodeSystem nhi-apply-reason</b></p><a name=\"nhi-apply-reason\"> </a><a name=\"hcnhi-apply-reason\"> </a><a name=\"nhi-apply-reason-en-US\"> </a><p>This case-sensitive code system <code>https://twcore.mohw.gov.tw/ig/pas/CodeSystem/nhi-apply-reason</code> defines the following codes:</p><table class=\"codes\"><tr><td style=\"white-space:nowrap\"><b>Code</b></td><td><b>Display</b></td></tr><tr><td style=\"white-space:nowrap\">C50P1<a name=\"nhi-apply-reason-C50P1\"> </a></td><td>早期乳癌-未發生腋下淋巴結轉移</td></tr><tr><td style=\"white-space:nowrap\">C50P2<a name=\"nhi-apply-reason-C50P2\"> </a></td><td>早期乳癌-具腋下淋巴結轉移</td></tr><tr><td style=\"white-space:nowrap\">C50R1<a name=\"nhi-apply-reason-C50R1\"> </a></td><td>轉移性乳癌</td></tr><tr><td style=\"white-space:nowrap\">C16R1<a name=\"nhi-apply-reason-C16R1\"> </a></td><td>轉移性胃癌</td></tr><tr><td style=\"white-space:nowrap\">P001<a name=\"nhi-apply-reason-P001\"> </a></td><td>黑色素瘤</td></tr><tr><td style=\"white-space:nowrap\">P011<a name=\"nhi-apply-reason-P011\"> </a></td><td>非小細胞肺癌-SQ-2線</td></tr><tr><td style=\"white-space:nowrap\">P012<a name=\"nhi-apply-reason-P012\"> </a></td><td>非小細胞肺癌-Adeno-3線</td></tr><tr><td style=\"white-space:nowrap\">P013<a name=\"nhi-apply-reason-P013\"> </a></td><td>非小細胞肺癌-1線</td></tr><tr><td style=\"white-space:nowrap\">P014<a name=\"nhi-apply-reason-P014\"> </a></td><td>鱗狀非小細胞肺癌第一線用藥(併用化療)</td></tr><tr><td style=\"white-space:nowrap\">P021<a name=\"nhi-apply-reason-P021\"> </a></td><td>小細胞肺癌(併用化療)</td></tr><tr><td style=\"white-space:nowrap\">P031<a name=\"nhi-apply-reason-P031\"> </a></td><td>典型何杰金氏淋巴瘤</td></tr><tr><td style=\"white-space:nowrap\">P041<a name=\"nhi-apply-reason-P041\"> </a></td><td>泌尿道上皮癌-2線</td></tr><tr><td style=\"white-space:nowrap\">P042<a name=\"nhi-apply-reason-P042\"> </a></td><td>泌尿道上皮癌-1線</td></tr><tr><td style=\"white-space:nowrap\">P043<a name=\"nhi-apply-reason-P043\"> </a></td><td>局部晚期或轉移性泌尿道上皮癌之維持療法</td></tr><tr><td style=\"white-space:nowrap\">P052<a name=\"nhi-apply-reason-P052\"> </a></td><td>胃癌-1線(併用化療)</td></tr><tr><td style=\"white-space:nowrap\">P061<a name=\"nhi-apply-reason-P061\"> </a></td><td>腎細胞癌</td></tr><tr><td style=\"white-space:nowrap\">P072<a name=\"nhi-apply-reason-P072\"> </a></td><td>晚期肝細胞癌-1線(併用標靶bevacizumab)</td></tr><tr><td style=\"white-space:nowrap\">P081<a name=\"nhi-apply-reason-P081\"> </a></td><td>頭頸部鱗狀細胞癌第二線用藥</td></tr><tr><td style=\"white-space:nowrap\">P082<a name=\"nhi-apply-reason-P082\"> </a></td><td>頭頸部鱗狀細胞癌第一線用藥</td></tr><tr><td style=\"white-space:nowrap\">P091<a name=\"nhi-apply-reason-P091\"> </a></td><td>默克細胞癌</td></tr><tr><td style=\"white-space:nowrap\">P101<a name=\"nhi-apply-reason-P101\"> </a></td><td>食道鱗狀細胞癌</td></tr><tr><td style=\"white-space:nowrap\">P111<a name=\"nhi-apply-reason-P111\"> </a></td><td>惡性肋膜間皮瘤(ipilimumab併用nivolumab 120mg)</td></tr></table></div>"
},
"url" : "https://twcore.mohw.gov.tw/ig/pas/CodeSystem/nhi-apply-reason",
"version" : "1.0.1",
"name" : "NHIApplyReason",
"title" : "NHI-健保事前審查-給付適應症",
"status" : "active",
"experimental" : false,
"date" : "2024-12-06",
"publisher" : "衛生福利部中央健康保險署",
"contact" : [
{
"name" : "衛生福利部中央健康保險署",
"telecom" : [
{
"system" : "url",
"value" : "https://www.nhi.gov.tw"
}
]
}
],
"description" : "臺灣衛生福利部中央健康保險署「給付適應症」代碼，代碼出版日期：2024-12-06；資料所屬單位：臺灣衛生福利部中央健康保險署。",
"caseSensitive" : true,
"content" : "complete",
"count" : 22,
"concept" : [
{
"code" : "C50P1",
"display" : "早期乳癌-未發生腋下淋巴結轉移"
},
{
"code" : "C50P2",
"display" : "早期乳癌-具腋下淋巴結轉移"
},
{
"code" : "C50R1",
"display" : "轉移性乳癌"
},
{
"code" : "C16R1",
"display" : "轉移性胃癌"
},
{
"code" : "P001",
"display" : "黑色素瘤"
},
{
"code" : "P011",
"display" : "非小細胞肺癌-SQ-2線"
},
{
"code" : "P012",
"display" : "非小細胞肺癌-Adeno-3線"
},
{
"code" : "P013",
"display" : "非小細胞肺癌-1線"
},
{
"code" : "P014",
"display" : "鱗狀非小細胞肺癌第一線用藥(併用化療)"
},
{
"code" : "P021",
"display" : "小細胞肺癌(併用化療)"
},
{
"code" : "P031",
"display" : "典型何杰金氏淋巴瘤"
},
{
"code" : "P041",
"display" : "泌尿道上皮癌-2線"
},
{
"code" : "P042",
"display" : "泌尿道上皮癌-1線"
},
{
"code" : "P043",
"display" : "局部晚期或轉移性泌尿道上皮癌之維持療法"
},
{
"code" : "P052",
"display" : "胃癌-1線(併用化療)"
},
{
"code" : "P061",
"display" : "腎細胞癌"
},
{
"code" : "P072",
"display" : "晚期肝細胞癌-1線(併用標靶bevacizumab)"
},
{
"code" : "P081",
"display" : "頭頸部鱗狀細胞癌第二線用藥"
},
{
"code" : "P082",
"display" : "頭頸部鱗狀細胞癌第一線用藥"
},
{
"code" : "P091",
"display" : "默克細胞癌"
},
{
"code" : "P101",
"display" : "食道鱗狀細胞癌"
},
{
"code" : "P111",
"display" : "惡性肋膜間皮瘤(ipilimumab併用nivolumab 120mg)"
}
]
}